Scholars Central

Conference abstractPublished 31 Oct 2016

Thrombolytic therapy by tissue plasminogen activator for pulmonary embolism

Authors: Md Shahidul Islam

Karolinska Institutet, Sweden; Uppsala University Hospital, Sweden

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Clinicians need to decide about the use of thrombolytic (fibrinolytic) therapy for pulmonary embolism (PE) after carefully considering the risks of major complications from bleeding, and benefits of the treatment for each individual patient. They should probably not use systemic thrombolysis for PE patients with normal blood pressure. Treatment by human recombinant tissue plasminogen activator (rt-PA), alteplase saves lives of high-risk PE patients, i.e., those with hypotension or shock. Even in the absence of strong evidence, clinicians need to choose the most appropriate regimen for administering alteplase for individual patients, based on assessment of the urgency of the situation, risks for major complications from bleeding and patients body-weights. In addition, invasive strategies should be considered when absolute contraindications for thrombolytic therapy exist, serious complications arise or thrombolytic therapy fails.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Internal Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternal Medicine
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Md Shahidul Islam”